Clinical trials: Oral Fungal Infection
Fungal Infections
Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)
The purpose of this study is to collect pharmacokinetic (PK) information related to how well posaconazole tablet is distributed in the body and to determine the safety of this new formulation.
- Trial name
- NCT01777763
- Testing
- Posaconazole 200 mg, Posaconazole 300 mg
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis, Oral, HIV Infections
A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole
To provide maintenance treatment with itraconazole solution for patients who were clinical responders in the ITR-USA-94 protocol, even if they subsequently relapsed.
- Trial name
- NCT00002341
- Testing
- Itraconazole
- Where
- United States
- Sponsor
- Janssen, LP
Bacterial Vaginosis, Recurrence
Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis
We are trying to determine if Oral Metronidazole with Lactobacillus Vaginal Suppositories is better than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis
- Trial name
- NCT03099408
- Testing
- Metronidazole Oral, "Metronidazole" and "Lactobacillus"
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University Shenzhen Hospital
Pseudomonas Infections
Lcr35 / ICU / P. Aeruginosa
Preventing carriage of potentially pathogenic micro-organisms from the aerodigestive tract is an infection control strategy used to reduce the occurrence of nosocomial infections - including ventilator-assisted pneumonia - in…
- Trial name
- NCT00621803
- Testing
- Probiotic Lactobacillus casei rhamnosus (Lcr35)
- Volunteers
- 400 people
- Sponsor
- University Hospital, Clermont-Ferrand
Bacterial Infections
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V.
- Trial name
- NCT02066402
- Testing
- Tedizolid (BAY119-2631), Linezolid
- Where
- 55 sites in United States, China and 2 more
- Volunteers
- 598 people
- Sponsor
- Bayer
Cholera
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
A Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the non-inferiority of immunogenicity and safety of single strain oral cholera vaccine Hillchol® (BBV131) to the comparator vaccine…
- Trial name
- Hillchol131 (NCT05732766)
- Testing
- Hillchol vaccine
- Where
- 9 sites in India
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Adverse Reaction to Cholera Vaccine, Cholera Vaccination Reaction
Extended Dose Intervals With Oral Cholera Vaccine in Cameroon
The primary aim of this project is to determine changes in the vibriocidal geometric mean titers (GMT) in subjects who receive the second dose of oral cholera vaccine (OCV) at different intervals: 2 weeks, 6 months, or 11 months…
- Trial name
- NCT03719066
- Testing
- killed whole cell oral cholera vaccine
- Where
- Cameroon
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Clostridium Difficile-associated Diarrhea (CDAD)
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
The purpose of this study was to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules in pediatric participants with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- SUNSHINE (NCT02218372)
- Testing
- Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid
- Where
- 44 sites in United States, Belgium and 8 more
- Volunteers
- 148 people
- Sponsor
- Astellas Pharma Europe B.V.
Complicated Urinary Tract Infection, Acute Pyelonephritis
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
This was a randomized, multicenter, multinational, double-blind study comparing the efficacy and safety of plazomicin compared with meropenem followed by optional oral (PO) therapy in the treatment of cUTI, including AP, in…
- Trial name
- EPIC (NCT02486627)
- Testing
- plazomicin, meropenem, levofloxacin (oral)
- Volunteers
- 609 people
- Sponsor
- Achaogen, Inc.
Vulvovaginal Candidiasis
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
- Trial name
- NCT05399641
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- Scynexis, Inc.
Multiple Erythema Migrans
Antibiotic Treatment of Multiple Erythema Migrans
The purpose of this study is to compare the efficacy and safety of 15-day ceftriaxone versus 15-day doxycycline treatment in patients with multiple erythema migrans.
- Trial name
- NCT01163994
- Testing
- ceftriaxone, doxycycline, erythema migrans patients treated with doxycycline
- Where
- Slovenia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Shigella
Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
- Trial name
- NCT00866242
- Testing
- CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Cholera, Vibrio Cholerae Infection
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
- Trial name
- NCT05453253
- Testing
- Delayed second dose of oral cholera vaccine, Euvichol-Plus, Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice
- Where
- Guinea
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Epicentre
Erythema Migrans, Erythema Chronicum Migrans
Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
Tick borne diseases are increasing in Norway. Lyme borreliosis is the most common infection. Erythema migrans is mainly diagnosed and treated in general practice.
- Conditions
- Erythema Migrans, Erythema Chronicum Migrans, Borreliosis, Lyme Disease
- Trial name
- NorTick_EM (NCT01368341)
- Testing
- Doxycycline, Phenoxymethylpenicillin, Amoxicillin
- Where
- Norway
- Volunteers
- 225 people
- Sponsor
- Morten Lindbaek
Bacterial Vaginosis
Title of the Protocol: Combined Use of Vaginal Clindamycin Cream and Oral Metronidazole Versus Oral Metronidazole
Bacterial vaginosis (BV) constitutes a gynecological condition characterized by an alteration of the vaginal microenvironment and more specifically an alteration of the normal Lactobacillus-dominated vaginal flora, to a flora…
- Trial name
- NCT07247851
- Testing
- Clindamycin Phosphate
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams Maternity Hospital
Clostridium Difficile Infection
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose exploration cohorts.
- Trial name
- NCT07649096
- Testing
- FZ002
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Oral Candidiases
Use of Maqui Berry Extract in Treating Oral Candidiasis in Diabetes Mellitus Patients and Systemically Healthy Persons
Fungi from the genus Candida present the saprophytic flora of the cavity. This saprophytic yeast can cause different form of oral infections at immunocompromised patients as well as at subjects with impaired local oral microbiota…
- Trial name
- NCT05916729
- Testing
- Miconazole, CandBerrol® lozenges
- Where
- Serbia
- Volunteers
- 90 people
- Sponsor
- University of Belgrade
Clostridium Difficile Infection
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
Cadazolid is a new antibiotic developed for the treatment of Clostridiun difficile associated diarrhea (CDAD), also known as Clostridium Difficile Infection (CDI).
- Trial name
- NCT01222702
- Testing
- Cadazolid, Vancomycin
- Where
- 23 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Actelion
Fungal Disease
ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects
This is a Phase 1, open-label, single center, non-randomized study to evaluate the absorption, distribution, metabolism and excretion (ADME) of an oral solution of radiolabeled Ibrexafungerp following repeat administration in…
- Trial name
- NCT05668429
- Testing
- Ibrexafungerp
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Scynexis, Inc.
Candidiasis, Oral, HIV Infections
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with…
- Trial name
- NCT00002112
- Testing
- Nystatin, Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer